Reconstitution and Storage of Tesamorelin: How to Properly Prepare and Store the Peptide

Tesamorelin is usually reconstituted by slowly adding bacteriostatic water (BAC water) or the supplied sterile diluent to the lyophilized peptide powder, then gently swirling the vial until fully dissolved and a clear solution is obtained [1–3]. Lyophilized means freeze-dried, which helps maintain peptide stability before reconstitution. Clinical formulations of tesamorelin are supplied as a lyophilized powder that must be dissolved before subcutaneous administration.

Because tesamorelin is a peptide-based drug, careful handling during reconstitution is important to maintain peptide stability and reduce the risk of degradation. Most preparation protocols recommend slowly injecting the diluent down the inside wall of the vial rather than directing the stream straight at the powder with high force. Vigorous shaking is typically avoided, as excessive mixing can contribute to peptide breakdown, foaming of the solution, or damage to the peptide's structure [1,3].

The general process for reconstituting tesamorelin typically involves the following steps:

• Wash your hands thoroughly and prepare a clean workspace.
• Clean the tesamorelin vial and BAC water vial using alcohol swabs.
• Draw the required amount of bacteriostatic water into a sterile syringe.
• Slowly inject water into the vial of tesamorelin.
• Allow the powder to dissolve naturally, gently swirling the vial as needed.
• Avoid aggressive shaking.
• Refrigerate the solution if it will not be used immediately.

After proper reconstitution, the tesamorelin solution should typically be clear and colorless. If the solution remains very cloudy, contains visible particles, changes color, or forms undissolved clumps, it may indicate improper storage, instability, or contamination.

Clinical trials using tesamorelin have used subcutaneous injections after reconstitution according to manufacturer's instructions, most commonly at a dose of 2 mg daily in studies of HIV-associated lipodystrophy and liver steatosis [4–7].

How much BAC Water for Tesamorelin? A Guide for 5mg, 10mg, and 20mg Vials

The amount of bacteriostatic water (BAC water) used to reconstitute tesamorelin may vary depending on preferred concentration and injection volume, however, many popular preparation methods utilize approximately 1–3 mL of BAC water for 5 mg or 10 mg vials to facilitate accurate dosing [1–3]. Clinical studies have primarily standardized tesamorelin by dose alone, rather than a single universal mixing volume.

For tesamorelin 5 mg vials, common mixing methods include:

• 1 mL BAC water for a more concentrated solution.
• 2 mL BAC water for easier dosing and milder injections.

For vials of tesamorelin 10 mg, commonly mentioned preparation methods include:

• 2 mL BAC water.
• 3 mL BAC water, which is often mentioned in peptide preparation protocols.

For tesamorelin 20 mg vials, some protocols use:

• Approximately 4–5 mL of BAC water, depending on the desired concentration and dosing schedule.

The main goal of reconstitution is to create a solution from which the prescribed dose can be accurately measured. The amount of BAC water added does not change the total amount of tesamorelin in the vial. It only changes the concentration of the final solution and the volume of liquid administered with each dose.

Clinical trials most commonly used a dose of 2 mg tesamorelin once daily administered subcutaneously [4–8]. A subcutaneous injection means that the drug is injected into the fatty tissue located directly beneath the skin.

When preparing tesamorelin:

• Slowly inject BAC water into the vial.
• Gently swirl the vial instead of shaking it vigorously.
• Ensure the solution becomes clear after complete dissolution.

Some commercial tesamorelin preparations contain manufacturer-specific diluents and mixing instructions; therefore, such instructions should always take precedence over general peptide preparation practices [1,2].

How to store Tesamorelin after reconstitution?

After reconstitution, tesamorelin is typically stored in a refrigerator at approximately 2–8°C (36–46°F) to help maintain the peptide’s stability and decrease its degradation [1–3]. Proper cooling is important because peptide compounds, like tesamorelin, can gradually lose stability when exposed to heat, repeated temperature fluctuations, or prolonged storage at room temperature.

Before reconstitution, lyophilized tesamorelin powder often remains stable at controlled room temperature if protected from excessive heat, moisture, and direct light [1,2]. However, once mixed with BAC water or another diluent, refrigeration becomes much more critical to maintain the integrity of the peptide solution.

General storage recommendations usually include:

• Store reconstituted tesamodelin in the refrigerator at 2–8°C.
• Keep the vial away from direct sunlight.
• Preventing solution freezing.
• Avoid repeating heating and cooling cycles.
• Applying sterile handling techniques to reduce the risk of contamination.

Manufacturer instructions for commercial tesamorelin products may recommend using the solution relatively soon after reconstitution rather than storing it long-term [1]. In research and peptide-use communities, some users store reconstituted tesamorelin in the refrigerator for a few days, though stability may vary depending on storage conditions and the type of diluent used.

Improper storage can increase the risk of peptide degradation, solution clouding, reduced efficacy, bacterial contamination, or solution thickening.

Clinical trials evaluating tesamorelin in the context of HIV-associated lipodystrophy, visceral fat reduction, and NAFLD have used strictly controlled storage and preparation conditions during treatment periods ranging from 26 weeks to 12 months [4–8].

Why does Tesamorelin become jelly-like or cloudy?

Tesamorelin can become cloudy, thick, gel-like, or form clumps due to improper mixing, temperature instability, peptide degradation, contamination, or incorrect storage conditions [1–3]. Peptides are structurally sensitive molecules, and visible changes in solution can sometimes indicate instability or issues during preparation.

A properly reconstituted tesamorelin solution should typically be clear and colorless upon mixing. Cloudiness or gelation may occur when:

• The peptide is vigorously vortexed during reconstitution.
• Very hot or very cold water is used.
• The solution experiences repeated temperature changes.
• The peptide is exposed to excessive heat or direct sunlight.
• Incorrect diluents are being used.
• Contamination occurs during preparation.
• The peptide partially denatures or aggregates. Aggregation means that the peptide molecules start to stick together.

Some individuals report that tesamorelin becomes gel-like when refrigerated or after prolonged storage. This can happen because peptide chains sometimes clump together under certain temperature or concentration conditions. Highly concentrated solutions may increase the risk of thickening or clouding.

Poor quality bacteriostatic water, expired diluent, or contamination during mixing can also contribute to visible changes in the solution. If particles, discoloration, persistent cloudiness, or abnormal gel formation appear, many protocols recommend discarding the solution, as the peptide's stability or sterility may no longer be reliable.

Tesamorelin used in clinical trials was prepared under strictly controlled pharmaceutical conditions, and the studies generally demonstrated good stability and tolerability when handled properly [4-8]. Injection site reactions were relatively common; however, serious problems related to formulation instability were not widely reported in controlled trials.

Typical practices for handling peptides often include:

• Using sterile materials.
• Refrigerate after reconstitution.
• Avoid vigorous shaking.
• Limiting repeated temperature changes.
• Protect the vial from excessive heat and light.

Disclaimer

The content is for educational and scientific information purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or instructions for pharmaceutical preparation. Tesamorelin is a prescription medication that requires medical supervision. Reconstitution procedures, dilution volumes, storage conditions, and administration methods may vary depending on the manufacturer, formulation, and official product instructions. Tesamorelin should only be prepared, stored, and administered according to manufacturer recommendations and under the supervision of a qualified healthcare professional. Improper mixing, storage, injection technique, or unsupervised peptide use may increase the risk of peptide degradation, contamination, adverse effects, or other complications.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Bookshelf: Tesamorelin Overview
2. PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information. Available at: PubChem Tesamorelin Summary
3. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
5. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
6. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058